Clinical Experience with α-Particle–Emitting 211At: Treatment of Recurrent Brain Tumor Patients with 211At-Labeled Chimeric Antitenascin Monoclonal Antibody 81C6-Reference-Cited by-同舟云学术

Clinical Experience with α-Particle–Emitting 211At: Treatment of Recurrent Brain Tumor Patients with 211At-Labeled Chimeric Antitenascin Monoclonal Antibody 81C6

Published:2007-12-12 Issue:1 Volume:49 Page:30-38
ISSN:0161-5505
Container-title:Journal of Nuclear Medicine
language:en
Short-container-title:J Nucl Med

Author:

Zalutsky Michael R.,Reardon David A.,Akabani Gamal,Coleman R. Edward,Friedman Allan H.,Friedman Henry S.,McLendon Roger E.,Wong Terence Z.,Bigner Darell D.

Publisher

Society of Nuclear Medicine

Subject

Radiology, Nuclear Medicine and imaging

Reference34 articles.

1. Outcomes and Prognostic Factors in Recurrent Glioma Patients Enrolled Onto Phase II Clinical Trials

2. Supratentorial malignant glioma: Patterns of recurrence and implications for external beam local treatment

3. Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results.

Cited by 346 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Future Treatment Strategies for Cancer Patients Combining Targeted Alpha Therapy with Pillars of Cancer Treatment: External Beam Radiation Therapy, Checkpoint Inhibition Immunotherapy, Cytostatic Chemotherapy, and Brachytherapy;Pharmaceuticals;2024-08-05

2. Recent advances in spatio-temporally controllable systems for management of glioma;Asian Journal of Pharmaceutical Sciences;2024-08

3. Transforming Cancer Treatment: The Evolving Landscape of Targeted α-Particle Therapy;Indian Cancer Awareness Journal;2024-07-29

4. Targeted Radionuclide Therapy in Glioblastoma;ACS Applied Materials & Interfaces;2024-07-23

5. PSMA-reactive NB7 single domain antibody fragment: A potential scaffold for developing prostate cancer theranostics;Nuclear Medicine and Biology;2024-07